Neurotoxicity of lead. Hypothetical molecular mechanisms of synaptic function disorders;Neurotoksyczność ołowiu. hipotetyczny molekularny mechanizm zaburzeń funkcji synaptycznych

Neurologia i Neurochirurgia Polska

Volumn 46, Issue 6, 2012, Pages 569-578

  Baranowska Bosiacka, Irena ^a   Gutowska, Izabela ^a   Rybicka, Marta ^a   Nowacki, Przemysław ^a   Chlubek, Dariusz ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

BDNF; Brain; Hippocampus; Lead (Pb); Neurotoxicity; NMDA receptor

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; LEAD; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

COGNITIVE DEFECT; ELECTROPHYSIOLOGY; HIPPOCAMPUS; HUMAN; LEAD POISONING; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR BIOLOGY; MOLECULAR MECHANICS; MOLECULAR TARGET; NERVE CELL PLASTICITY; NEUROTOXICITY; REVIEW; SIGNAL TRANSDUCTION; SYNAPSE;

EID: 84875138426     PISSN: 00283843     EISSN: 18974260     Source Type: Journal    
DOI: 10.5114/ninp.2012.31607     Document Type: Review

References (68)

1. CDC 2004 (Centers For Disease Control And Prevention). National Center For Environmental Health. A review of evidence of health effects of blood lead levels < 10 μg/dl in children. Atlanta; available at: http://www.cdc.gov/nceh/lead/ACCLPP/meetingMinutes/lessThan10MtgMAR04.pdf.
2. CDC 2005 (Centers For Disease Control And Prevention). National Center For Environmental Health. Preventing lead poisoning in young children. Atlanta.
3. EP. 2005 (Environmental Protection). The restriction of the use of certain hazardous substances in electrical and electronic equipment regulations No. 2748; available at: http://www.legislation.gov.uk/uksi/2005/2748/pdfs/uksi_20052748_en.pdf.
4. EP. 2009 (Environmental Protection). The restriction of the use of certain hazardous substances in electrical and electronic equipment (amendment) regulations, No. 581; available at: http://www.legislation.gov.uk/uksi/2009/581/pdfs/uksi_20090581_en.pdf
5. EU. 2008 (European Commission). Institute For Health And Consumer Protection Toxicology And Chemical Substances (& ECB). Opinion of the TC NES on the Environment Part of Industry Voluntary Risk Assessments on Lead and Lead Compounds; available at: http://echa.europa.eu/doc/trd_substances/VRAR/Lead/tcnes_opinion/tcnes_opinion_env.pdf.
6. Neal A.P., Worley P.F., Guilarte T.R. Lead exposure during synaptogenesis alters NMDA receptor targeting via NMDA receptor inhibition. Neurotoxicology 2011; 32: 281-289.
7. Koller K., Brown T., Spurgeon A., et al. Recent developments in low-level lead exposure and intellectual impairment in children. Environ Health Perspect 2004; 112: 987-994.
8. Lanphear B.P., Hornung R., Khoury J., et al. Low-level environmental lead exposure and children's intellectual function: an international pooled analysis. Environ Health Perspect 2005; 113: 894-849.
9. Gulson B., Mizon K., Smith H., et al. Skeletal lead release during bone resorption: effect of bisphosphonate treatment in a pilot study. Environ Health Perspect 2002; 110: 1017-1023.
10. Garrido Latorre F., Hernández-Avila M., Tamayo Orozco J., et al. Relationship of blood and bone lead to menopause and bone mineral density among middle-age women in Mexico City. Environ Health Perspect 2003; 111: 631-636.
11. Nash D., Magder L.S., Sherwin R., et al. Bone density-related predictors of blood lead level among peri- and postmenopausal women in the United States: The Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2004; 160: 901-911.
12. Riedt C.S., Buckley B.T., Brolin R.E., et al. Blood lead levels and bone turnover with weight reduction in women. J Expo Sci Environ Epidemiol 2009; 19: 90-96.
13. Canfield R.L., Henderson C.R., Cory-Slechta D.A., et al. Intellectual impairment in children with blood lead concentrations below 10 microg per deciliter. N Engl J Med 2003; 348: 1517-1526.
14. Jakubowski M. Low-level environmental lead exposure and intellectual impairment in children-the current concepts of risk assessment. Int J Occup Med Environ Health 2011; 24: 1-7.
15. Rogan W.J., Dietrich K.N., Ware J.H., et al. The effect of chelation therapy with succimer on neuropsychological development in children exposed to lead. N Engl J Med 2001; 344: 1421-1426.
16. Braun J.M., Kahn R.S., Froehlich T., et al. Exposures to environmental toxicants and attention deficit hyperactivity disorder in U.S. children. Environ Health Perspect 2006; 14: 1904-1909.
17. Eubig P.A., Aguiar A., Schantz S.L. Lead and PCBs as risk factors for attention deficit/hyperactivity disorder. Environ Health Perspect 2010; 118: 1654-1667.
18. Needleman H.L., McFarland C., Ness R.B., et al. Bone lead levels in adjudicated delinquents. A case control study. Neurotoxicol Teratol 2002; 24: 711-717.
19. Wright J.P., Dietrich K.N., Ris M.D., et al. Association of prenatal and childhood blood lead concentrations with criminal arrests in early adulthood. PLoS Med 2008; 27: e101.
20. Hrubá F., Strömberg U., Černá M., et al. Blood cadmium, mercury, and lead in children: an international comparison of cities in six European countries, and China, Ecuador, and Morocco. Environ Int 2012; 41: 29-34.
21. Stroh E., Lundh T., Oudin A., et al. Geographical patterns in blood lead in relation to industrial emissions and traffic in Swedish children, 1978-2007. BMC Public Health 2009; 9: 225.
22. Barton H.J. Advantages of the use of deciduous teeth, hair, and blood analysis for lead and cadmium bio-monitoring in children. A study of 6-year-old children from Krakow (Poland). Biol Trace Elem Res 2011; 143: 637-658.
23. Jones R.L., Homa D.M., Meyer P.A., et al. Trends in blood lead levels and blood lead testing among US children aged 1 to 5 years, 1988-2004. Pediatrics 2009; 123: 376-385.
24. Costa L.G., Aschner M., Vitalone A., et al. Developmental neuropathology of environmental agents. Annu Rev Pharmacol Toxicol 2004; 44: 87-110.
25. Mendola P., Selevan S.G., Gutter S., et al. Environmental factors associated with a spectrum of neurodevelopmental deficits. Ment Retard Dev Disabil Rev 2002; 8: 188-197.
26. Haraguchi T., Ishizu H., Kawai K., et al. Diffuse neurofibrillary tangles with calcification (a form of dementia): X-ray spectrometric evidence of lead accumulation in calcified regions. Neuroreport 2001; 12: 1257-1260.
27. Basha R., Reddy G.R. Developmental exposure to lead and late life abnormalities of nervous system. Indian J Exp Biol 2010; 48: 636-641.
28. Baranowska-Bosiacka I., Dabrowska-Bouta B., Struzyńska L. Regional changes in purines and selected purinergic receptors in immature rat brain exposed to lead. Toxicology 2011; 279: 100-107.
29. Struzynska L., Dabrowska-Bouta B., Koza K., et al. Inflammation- like glial response in lead-exposed immature rat brain. Toxicol Sci 2007; 95: 156-162.
30. Cakała M., Strosznajder J.B. The role of cyclooxygenases in neurotoxicity of amyloid beta peptides in Alzheimer's disease. Neurol Neurochir Pol 2010; 44: 65-79.
31. Kuhn W., Winkel R., Woitalla D., et al. High prevalence of Par - kinsonism after occupational exposure to lead-sulfate batteries. Neurology 1998; 50: 1885-1886.
32. Coon S., Stark A., Peterson E., et al. Whole-body lifetime occupational lead exposure and risk of Parkinson's disease. Environ Health Perspect 2006; 114: 1872-1876.
33. Kamel F. Lead and other neurotoxins as a risk factors for amyotrophic lateral sclerosis. Crisp Data Base National Institute of Health. 2003. http://toxnet.nlm.nih.gov.
34. Fang F., Kwee L.C., Allen K.D., et al. Association between blood lead and the risk of amyotrophic lateral sclerosis. Am J Epidemiol 2010; 171: 1126-1133.
35. Zheng G., Tian L., Liang Y., et al. δ-Aminolevulinic acid dehydratase genotype predicts toxic effects of lead on workers' peripheral nervous system. Neurotoxicology 2011; 32: 374-382.
36. Bilińska M., Brzezowska D., Koszewicz M., et al. Subclinical lead neuropathy. Pol Merkur Lek 2004; 17: 244-247.
37. Bilińska M., Antonowicz-Juchniewicz J., Koszewicz M., et al. Distribution of conduction velocity in the ulnar nerve among lead exposed workers. Med Pr 2005; 56: 139-146.
38. Baranowska-Bosiacka I., Chlubek D. Biochemical mechanisms of neurotoxic lead activity. Poste{ogonek}py Biochem 2006; 52: 320-329.
39. Gavazzo P., Zanardi I., Baranowska-Bosiacka I., et al. Molecular determinants of Pb2+ interaction with NMDA receptor channels. Neurochem Int 2008; 52: 329-337.
40. Marchetti C., Gavazzo P. NMDA receptors as targets of heavy metal interaction and toxicity. Neurotox Res 2005; 8: 245-258.
41. Albensi B.C. The NMDA receptor/ion channel complex: a drug target for modulating synaptic plasticity and excitotoxicity. Cur Pharm Des 2007; 13: 3185-3194.
42. Niewoehner B., Single F.N., Hvalby Ø., et al. Impaired spatial working memory but spared spatial reference memory following functional loss of NMDA receptors in the dentate gyrus. Eur J Neurosci 2007; 25: 837-846.
43. Takeda A., Itagaki K., Ando M., et al. Involvement of N-methyl- D-aspartate receptor subunits in zinc-mediated modification of CA1 long-term potentiation in the developing hippocampus. J Neurosci Res 2012; 90: 551-558.
44. Howland J.G., Wang Y.T. Synaptic plasticity in learning and memory: stress effects in the hippocampus. Prog Brain Res 2008; 169: 145-158.
45. Johnstone V.P., Raymond C.R. A protein synthesis and nitric oxide-dependent presynaptic enhancement in persistent forms of long-term potentiation. Learn Mem 2011; 18: 625-633.
46. Miyamoto E. Molecular mechanism of neuronal plasticity: induction and maintenance of long-term potentiation in the hippocampus. J Pharmacol Sci 2006; 100: 433-442.
47. Hori N., Büsselberg D., Matthews M.R., et al. Lead blocks LTP by an action not at NMDA receptors. Exp Neurol 1993; 19: 192-197.
48. Lau A., Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch 2010; 460: 525-542.
49. Van Dongen A.M. Biology of the NMDA Receptor. CRC Press, Boca Raton 2009.
50. Monyer H., Sprengel R., Schoepfer R., et al. Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science 1992; 256: 1217-1221.
51. Büsselberg D., Michael D., Platt B. Pb2+ reduces voltage- and N-methyl-D-aspartate (NMDA)-activated calcium channel currents. Cell Mol Neurobiol 1994; 14: 711-722.
52. Guilarte T.R., Miceli R.C., Jett D.A. Biochemical evidence of an interaction of lead at the zinc allosteric sites of the NMDA re captor complex: effects of neuronal development. Neurotoxicology 1995; 16: 63-71.
53. Lasley S.M., Gilbert M.E. Lead inhibits the rat N-methyl-Daspartate receptor channel by binding to a site distinct from the zinc allosteric site. Toxicol Appl Pharmacol 1999; 159: 224-233.
54. Goldstein G.W. Evidence that lead acts as a calcium substitute in second messenger metabolism. Neurotoxicology 1993; 14: 97-101.
55. Baranowska-Bosiacka I., Gutowska I., Marchlewicz M., et al. Disrupted pro- and antioxidative balance as a mechanism of neurotoxicity induced by perinatal exposure to lead. Brain Res 2012; 1435: 56-71.
56. Zhang X.Y., Liu A.P., Ruan D.Y., et al. Effect of developmental lead exposure on the expression of specific NMDA receptor subunit mRNAs in the hippocampus of neonatal rats by digoxigenin-labeled in situ hybridization histochemistry. Neurotoxicol Teratol 2002; 24: 149-160.
57. Cordova F.M., Rodrigues A.L., Giacomelli M.B., et al. Lead stimulates ERK1/2 and p38MAPK phosphorylation in the hippocampus of immature rats. Brain Res 2004; 998: 65-72.
58. Zhang G.S., Ye W.F., Tao R.R., et al. Expression profiling of Ca(2+)/calmodulin-dependent signaling molecules in the rat dorsal and ventral hippocampus after acute lead exposure. Exp Toxicol Pathol 2012; 64: 619-624.
59. Cohen-Cory S., Kidane A.H., Shirkey N.J., et al. Brain-derived neurotrophic factor and the development of structural neuronal connectivity. Dev Neurobiol 2010; 70: 271-288.
60. Neal A.P, Stansfield K.H., Worley P.F., et al. Lead exposure during synaptogenesis alters vesicular proteins and impairs vesicular release: potential role of NMDA receptor-dependent BDNF signaling. Toxicol Sci 2010; 116: 249-263.
61. Jiang X., Tian F., Mearow K., et al. The excitoprotective effect of N-methyl-D-aspartate receptors is mediated by a brainderived neurotrophic factor autocrine loop in cultured hippo - campal neurons. J Neurochem 2005; 94: 713-722.
62. Walz C., Jüngling K., Lessmann V., et al. Presynaptic plasticity in an immature neocortical network requires NMDA receptor activation and BDNF release. J Neurophysiol 2006; 96: 3512-3516.
63. Kolarow R., Brigadski T., Lessmann V. Postsynaptic secretion of BDNF and NT-3 from hippocampal neurons depends on calcium calmodulin kinase II signaling and proceeds via delayed fusion pore opening. J Neurosci 2007; 27: 10350-10364.
64. Chen Q., He S., Hu X.L., et al. Differential roles of NR2Aand NR2B-containing NMDA receptors in activity-dependent brain-derived neurotrophic factor gene regulation and limbic epileptogenesis. J Neurosci 2007; 27: 542-552.
65. Pozzo-Miller L.D., Gottschalk W., Zhang L., et al. Impairments in high-frequency transmission, synaptic vesicle docking, and synaptic protein distribution in the hippocampus of BDNF knockout mice. J Neurosci 1999; 19: 4972-4983.
66. Neal A.P., Guilarte T.R. Molecular neurobiology of lead (Pb(2+)): effects on synaptic function. Mol Neurobiol 2010; 42: 151-160.
67. Hardingham G.E., Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci 2010; 11: 682-696.
68. Finkelstein Y., Markowitz M.E., Rosen J.F. Low-level lead induced neurotoxicity in children: an update on central nervous system effects. Brain Res Rev 1998; 27: 168-176.